Perhexiline - Heart Metabolics

Drug Profile

Perhexiline - Heart Metabolics

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator HMBL Limited
  • Developer Heart Metabolics Limited
  • Class Antihypertensives; Cyclohexanes; Ischaemic heart disorder therapies; Piperidines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Carnitine O-palmitoyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypertrophic cardiomyopathy

Most Recent Events

  • 12 Jul 2017 Heart Metabolics withdraws a phase III trial prior to enrolment for Hypertrophic cardiomyopathy in USA due to lack of efficacy in a preceding study (PO) (NCT02431221)
  • 01 Aug 2016 Phase-II clinical trials in Hypertrophic cardiomyopathy in USA (PO) (NCT02862600)
  • 16 Apr 2015 Heart Metabolics receives Special Protocol Assessment from the US FDA for a phase III trial of perhexiline for Hypertrophic cardiomyopathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top